May 9, 2020 10:33 AM EDTUpdated May 12, 04:08 AM
Coronavirus

Covid-19 roundup: Charles Riv­er gets slammed by the pan­dem­ic; For­mer Sanofi R&D chief Elias Zer­houni heads a list of can­di­dates for Covid-19 drug czar; Feds try to sort out remde­sivir dis­tri­b­u­tion mess

John Carroll

Editor & Founder

Natalie Grover

Reporter

Jason Mast

Editor

Charles Riv­er Labs $CRL, the big CRO that spe­cial­izes in pre­clin­i­cal re­search pro­grams, cruised through Q1 with a boom­ing bio­phar­ma in­dus­try feed­ing its op­er­a­tions with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times